Literature DB >> 23751850

Comment on: Rifaximin in the treatment of irritable bowel syndrome. is there a high risk for development of antimicrobial resistance?

Fiorella Calanni1, Cecilia Renzulli, Maria V Fogli, Miriam Barbanti.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23751850     DOI： 10.1097/MCG.0b013e3182951b6c

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN： 0192-0790            Impact factor:   3.062


× No keyword cloud information.
  2 in total

1.  Impact of Antibiotic Resistance Genes in Gut Microbiome of Patients With Cirrhosis.

Authors:  Amirhossein Shamsaddini; Patrick M Gillevet; Chathur Acharya; Andrew Fagan; Edith Gavis; Masoumeh Sikaroodi; Sara McGeorge; Alexander Khoruts; Somaya Albhaisi; Michael Fuchs; Richard K Sterling; Jasmohan S Bajaj
Journal:  Gastroenterology       Date:  2021-04-20       Impact factor: 33.883

2.  Determination of rifaximin treatment period according to lactulose breath test values in nonconstipated irritable bowel syndrome subjects.

Authors:  Suhyun Bae; Kwang Jae Lee; Young-Sang Kim; Kyu-Nam Kim
Journal:  J Korean Med Sci       Date:  2015-05-13       Impact factor: 2.153
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.